Goodwin advised SpringWorks Therapeutics, Inc. on the offering. American precision medicine company SpringWorks Therapeutics (Nasdaq: SWTX) has closed a public offering of 10,905,171 shares of its common...
SpringWorks Therapeutics’ $316.25 Million Underwritten Common Stock Offering
Quest Diagnostics’ Acquisition of Haystack Oncology
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...